Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methamphetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.62 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.62 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LAP3 | P28838 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methamphetamine SCHEMBL4377972 | 1.00 | SIGMAR1 (0.62) | SIGMAR1TAAR1SLC18A2NPC1RAB9A | |
| Methamphetamine SCHEMBL4390313 | 0.86 | TAAR1 (0.68) | SIGMAR1TAAR1SLC18A2NPC1RAB9A | |
| Methamphetamine SCHEMBL4390312 | 0.86 | TAAR1 (0.68) | SIGMAR1TAAR1SLC18A2NPC1RAB9A | |
| Methamphetamine SCHEMBL28489401 | 0.86 | TAAR1 (0.78) | SIGMAR1TAAR1SLC18A2NPC1RAB9A | |
| Amphetamine SCHEMBL4387791 | 0.82 | SLC6A4 (0.59) | SIGMAR1TAAR1PIN1LAP3 | |
| Methamphetamine SCHEMBL27438559 | 0.80 | SIGMAR1 (0.95) | SIGMAR1TAAR1SLC18A2NPC1RAB9A | |
| Methamphetamine SCHEMBL28959450 | 0.79 | SIGMAR1 (0.84) | SIGMAR1TAAR1SLC18A2NPC1RAB9A | |
| Methamphetamine SCHEMBL18985124 | 0.79 | SIGMAR1 (0.84) | SIGMAR1TAAR1SLC18A2NPC1RAB9A | |
| Methamphetamine SCHEMBL18227057 | 0.79 | SIGMAR1 (0.91) | SIGMAR1TAAR1SLC18A2NPC1RAB9A | |
| Methamphetamine SCHEMBL20211416 | 0.79 | SIGMAR1 (1.00) | SIGMAR1TAAR1SLC18A2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121029-A2 | PRODRUGS AND METHODS OF MAKING AND USING THE SAME | Neurogesx, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080318905-A1 | Prodrugs and methods of making and using the same | NEUROGESX, INC. | 2008-12-25 | — | — | US | disclosed |
| WO-2008070149-A2 | PRODRUGS AND METHODS OF MAKING AND USING THE SAME | NEUROGESX, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318905-A1 | Prodrugs and methods of making and using the same | NAPEPLD, CES2, MTAP | SIGMAR1 173/4885TAAR1 497/4885SLC18A2 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.